Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Myocardial Infarction

Myocardial Infarction

Myocardial Infarction is a serious condition where the blood supply to a part of the heart muscle is suddenly blocked, often due to a blood clot.
This can lead to damage or death of the affected heart tissue.
Symptoms may include chest pain, shortness of breath, and nausea.
Timely treatment is crucial to minimize damage and improve outcomes.
PubCompare.ai can help optimize your Myocardial Infarction research by locating the best protocols from literature, pre-prints, and patents, and leveraging AI-driven comparisons to enhance reproducibility and accuaracy, ensuring your research is on the right track.

Most cited protocols related to «Myocardial Infarction»

1
Statin Prescription and Cardiovascular Outcomes
We used data on 9104 patients who were discharged alive following hospitalization with a diagnosis of acute myocardial infarction (AMI or heart attack) from 102 hospitals in Ontario, Canada, between April 1, 1999 and March 31, 2001. These data are similar to those reported on elsewhere [13 (link)–15 (link)], and were collected as part of the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) Study, an initiative focused on improving the quality of care for cardiovascular disease patients in Ontario [16 ]. Data on patient demographics, presenting signs and symptoms, classic cardiac risk factors, comorbid conditions and vascular history, vital signs on admission, and results of laboratory tests, were abstracted directly from patients’ medical records. The exposure of interest was whether the patient was prescribed a statin at hospital discharge. Overall, 3049 (33.5 per cent) of patients received a prescription for a statin at discharge, while 6055 (66.5 per cent) did not receive a prescription at discharge. Table I compares the means of continuous baseline covariates and prevalences of dichotomous baseline covariates between treated and untreated subjects in the original unmatched sample. The prevalence of dichotomous variables was compared between treated and untreated subjects using a Chi-squared test, while a standard two-sample t-test was used to compare continuous baseline covariates.
, & Austin P.C. (2009). Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statistics in Medicine, 28(25), 3083-3107.
Full text: Click here
Publication 2009
Blood Vessel Cardiovascular Diseases Diagnosis Heart Hospitalization Hydroxymethylglutaryl-CoA Reductase Inhibitors Myocardial Infarction Patient Discharge Patients Quality of Health Care Signs, Vital
2
Mediterranean Diet Adherence Assessment
At baseline, registered dietitians completed a 14-item Mediterranean Diet adherence screener (Table 1) in a face-to-face interview with the participant [21] (link), [27] –[29] (link). The dietitians had been previously trained and certified to implement the PREDIMED protocol and had been hired to work full-time for the trial. The 14-item tool was developed in a Spanish case-control study of myocardial infarction [30] (link), where the best cut-off points for discriminating between cases and controls were selected for each food or food group. With this first step, 9 of the 14 items were obtained [31] (link). Five additional items that were felt to be especially relevant to assess adherence to the traditional Mediterranean diet were subsequently added. Two of these items used short questions to inquire on food habits: Do you use olive oil as the principal source of fat for cooking? and Do you prefer to eat chicken, turkey or rabbit instead of beef, pork, hamburgers or sausages? The other 3 items inquired on frequency of consumption of nuts, soda drinks and a typical Mediterranean sauce (“sofrito”): How many times do you consume nuts per week? How many carbonated and/or sugar-sweetened beverages do you consume per day? How many times per week do you consume boiled vegetables, pasta, rice, or other dishes with a sauce (“sofrito”) of tomato, garlic, onion, or leeks sauteed in olive oil?[26] (link).
The baseline 14-item questionnaire (Table 1) was the primary measure used in this study to appraise adherence of participants to the Mediterranean diet. In addition, a full-length 137-item validated FFQ [32] (link) was also administered to all participants. We obtained information about total energy intake and alcohol intake (only with descriptive purposes) from this FFQ. In the validation study, the score obtained with brief 14-item questionnaire correlated significantly with that obtained from the full-length FFQ score (Pearson correlation coefficient (r) = 0.52; intraclass correlation coefficient = 0.51). Associations in the anticipated directions for the different dietary intakes reported on the FFQ were found [26] (link). Significant inverse correlations of the 14-item tool with fasting glucose, total:HDL cholesterol ratio, triglycerides and the 10-y estimated coronary artery disease risk also supported the validity of this brief Mediterranean diet adherence screener [26] (link).
Also a general medical questionnaire, and the validated Spanish version of the Minnesota Leisure-Time Physical Activity Questionnaire [33] (link)–[34] (link) were collected by the dietitians in the personal interview with each participant [21] (link). Weight, height and WC were directly measured by registered nurses who had been previously trained and certified to implement the PREDIMED protocol and were hired to work full-time for this trial, as previously described [21] (link), [27] –[29] (link). The WHtR was calculated as WC divided by height, both in centimeters.
Martínez-González M.A., García-Arellano A., Toledo E., Salas-Salvadó J., Buil-Cosiales P., Corella D., Covas M.I., Schröder H., Arós F., Gómez-Gracia E., Fiol M., Ruiz-Gutiérrez V., Lapetra J., Lamuela-Raventos R.M., Serra-Majem L., Pintó X., Muñoz M.A., Wärnberg J., Ros E, & Estruch R. (2012). A 14-Item Mediterranean Diet Assessment Tool and Obesity Indexes among High-Risk Subjects: The PREDIMED Trial. PLoS ONE, 7(8), e43134.
Full text: Click here
Publication 2012
Allium cepa Beef Chickens Coronary Arteriosclerosis Diet, Mediterranean Dietitian Face Feelings Food Garlic Glucose High Density Lipoprotein Cholesterol Hispanic or Latino Hyperostosis, Diffuse Idiopathic Skeletal Leeks Myocardial Infarction Nuts Oil, Olive Oryza sativa Pastes Physical Examination Pork Rabbits Registered Nurse Sugar-Sweetened Beverages Tomatoes Triglycerides Vegetables
3
Gait Speed and Survival in Older Adults
Gait speed was calculated for each participant using distance in meters and time in seconds. All studies used instructions to walk at usual pace and from a standing start. The walk distance varied from 8 ft to 6 m. For 8 ft, we converted to 4-m gait speed by formula.24 (link) For 6 m, we created a conversion formula (4-m speed=−0.0341 + (6-mspeed)×0.9816 withR2=0.93, based on a cohort of 61 individuals with concurrent 4- and 6-m walks). For 15 feet (4.57 m),23 (link) speed was simply meters divided by time. Where available, data on fast gait speed (walk as fast as comfortably able25 (link)) and the Short Physical Performance Battery were obtained.26 (link) Survival for each individual used study monitoring methods, including the National Death Index and individual study follow-up. Time from gait speed baseline to death was calculated in days. Five-year survival status was confirmed for more than 99% of participants.
Additional variables include sex, age, race/ethnicity (white, black, Hispanic, other, defined by participant), height(centimeters), weight(kilograms), body mass index (BMI), calculated as weight in kilograms divided by height in meters squared (<25, 25–30, and >30), smoking (never, past, current), use of mobility aids (none, cane, walker), systolic blood pressure, self-reports of health (excellent or very good vs good, fair, or poor), hospitalization in the past year (yes/no), and physician-diagnosed medical conditions (cancer, arthritis, diabetes, and heart disease, all yes/no). Measures of self-reported functional status were not collected in all studies and varied in content and form. We created a dichotomous variable reflecting dependence in basic activities of daily living (ADLs) based on report of being unable or needing help from another person to perform any basic activity, including eating, toileting, hygiene, transfer, bathing, and dressing. For individuals independent in ADLs, we created a dichotomous variable reflecting difficulty in instrumental ADLs based on report of difficulty or dependence with shopping, meal preparation, or heavy housework due to a health or physical problem. Participants were then classified into 1 of 3 groups; dependent in ADLs, difficulty with instrumental ADLs, or independent. Physical activity data were collected in 6 studies, but time frames and items varied widely. Two studies used the Physical Activity Scale for the Elderly (PASE).27 (link) We dichotomized the PASEs core at 100.28 (link) We created operational definitions of other covariates that were reasonably consistent across studies. Covariates were identical for height, weight, BMI, and systolic blood pressure. Hospitalization within the prior year was determined largely by self-report, and chronic conditions were by self-report of physician diagnosis, with heart disease encompassing angina, coronary artery disease, heart attack, and heart failure.
Studenski S., Perera S., Patel K., Rosano C., Faulkner K., Inzitari M., Brach J., Chandler J., Cawthon P., Connor E.B., Nevitt M., Visser M., Kritchevsky S., Badinelli S., Harris T., Newman A.B., Cauley J., Ferrucci L, & Guralnik J. (2011). Gait Speed and Survival in Older Adults. JAMA : the journal of the American Medical Association, 305(1), 50-58.
Publication 2011
Acquired Immunodeficiency Syndrome Aged Angina Pectoris Arthritis Canes Chronic Condition Congestive Heart Failure Coronary Artery Disease Diabetes Mellitus Diagnosis Ethnicity Foot Heart Diseases Hispanics Hospitalization Index, Body Mass Malignant Neoplasms Myocardial Infarction Neoplasm Metastasis Performance, Physical Physical Examination Physicians Range of Motion, Articular Reading Frames Systolic Pressure Walkers
4
Intensive Blood Pressure Reduction Outcomes
Definitions of study outcomes are outlined in the Supplementary Appendix. A committee whose members were unaware of the study-group assignments adjudicated the clinical outcomes specified in the protocol. The primary hypothesis was that treatment to reach a systolic blood-pressure target of less than 120 mm Hg, as compared with a target of less than 140 mm Hg, would result in a lower rate of the composite outcome of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes. Secondary outcomes included the individual components of the primary composite outcome, death from any cause, and the composite of the primary outcome or death from any cause.
We also assessed renal outcomes, using a different definition for patients with chronic kidney disease (eGFR <60 ml per minute per 1.73 m2) at baseline and those without it. The renal outcome in participants with chronic kidney disease at baseline was a composite of a decrease in the eGFR of 50% or more (confirmed by a subsequent laboratory test) or the development of ESRD requiring long-term dialysis or kidney transplantation. In participants without chronic kidney disease at baseline, the renal outcome was defined by a decrease in the eGFR of 30% or more to a value of less than 60 ml per minute per 1.73 m2. Incident albuminuria, defined for all study participants by a doubling of the ratio of urinary albumin (in milligrams) to creatinine (in grams) from less than 10 at baseline to greater than 10 during follow-up, was also a prespecified renal outcome.
Prespecified subgroups of interest for all outcomes were defined according to status with respect to cardiovascular disease at baseline (yes vs. no), status with respect to chronic kidney disease at baseline (yes vs. no), sex, race (black vs. non-black), age (<75 vs. ≥75 years), and baseline systolic blood pressure in three levels (≤132 mm Hg, >132 to <145 mm Hg, and ≥145 mm Hg). We also planned a comparison of the effects of systolic blood-pressure targets on incident dementia, changes in cognitive function, and cerebral small-vessel ischemic disease; these results are not presented here.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. (2015). The New England journal of medicine, 373(22), 2103-2116.
Publication 2015
Acute Coronary Syndrome Albumins Cardiovascular Diseases Cardiovascular System Cerebral Small Vessel Diseases Cerebrovascular Accident Chronic Kidney Diseases Cognition Congestive Heart Failure Creatinine Dementia Dialysis EGFR protein, human Kidney Kidney Failure, Chronic Kidney Transplantation Myocardial Infarction Patients Systolic Pressure Urine
5
Genetic Risk Score for Blood Pressure and Cardiovascular Disease
We calculated a weighted genetic risk score (GRS) (Supplementary Table 24) to provide an estimate of the combined effect of the BP raising variants on BP and risk of hypertension and applied this to the UKB data (Supplementary Methods). Our analysis included 423,713 unrelated individuals of European ancestry of whom 392,092 individuals were free of cardiovascular events at baseline.
We assessed the association of the continuous GRS variable on BP and with the risk of hypertension, with and without adjustment for sex. We then compared BP levels and risk of hypertension, respectively, for individuals in the top vs bottom quintiles of the GRS distribution. Similar analyses were performed for the top vs bottom deciles of the GRS distribution. All analyses were restricted to the 392,092 unrelated individuals of European ancestry from UKB. As a sensitivity analysis to assess for evidence of bias in the UKB results, we also carried out similar analyses in Airwave, an independent cohort of N=14,004 unrelated participants of European descent30 (link) (Supplementary Methods).
We calculated the association of the GRS with cardiovascular disease in unrelated participants in UKB data, based on self-reported medical history, and linkage to hospitalization and mortality data (Supplementary Table 25). We use logistic regression with binary outcome variables for composite incident cardiovascular disease (Supplementary Methods), incident myocardial infarction and incident stroke (using the algorithmic UKB definitions) and GRS as explanatory variable (with and without sex adjustment).
We also assessed the association of this GRS with BP in unrelated individuals Africans (N=6,970) and South Asians (N=8,827) from the UKB to see whether BP-associated SNPs identified from GWAS predominantly in Europeans are also associated with BP in populations of non-European ancestry.
We calculated the percentage of variance in BP explained by genetic variants using the independent Airwave cohort (N=14,004) (Supplementary Methods). We considered three different levels of the GRS: (i) all pairwise-independent, LD-filtered (r2 < 0.1) published SNPs within the known loci; (ii) all known SNPs and sentinel SNPs at novel loci; (iii) all independent signals at all 901 known and novel loci including the 163 secondary SNPs.
Evangelou E., Warren H.R., Mosen-Ansorena D., Mifsud B., Pazoki R., Gao H., Ntritsos G., Dimou N., Cabrera C.P., Karaman I., Ng F.L., Evangelou M., Witkowska K., Tzanis E., Hellwege J.N., Giri A., Velez Edwards D.R., Sun Y.V., Cho K., Gaziano J.M., Wilson P.W., Tsao P.S., Kovesdy C.P., Esko T., Mägi R., Milani L., Almgren P., Boutin T., Debette S., Ding J., Giulianini F., Holliday E.G., Jackson A.U., Li-Gao R., Lin W.Y., Luan J., Mangino M., Oldmeadow C., Prins B.P., Qian Y., Sargurupremraj M., Shah N., Surendran P., Thériault S., Verweij N., Willems S.M., Zhao J.H., Amouyel P., Connell J., de Mutsert R., Doney A.S., Farrall M., Menni C., Morris A.D., Noordam R., Paré G., Poulter N.R., Shields D.C., Stanton A., Thom S., Abecasis G., Amin N., Arking D.E., Ayers K.L., Barbieri C.M., Batini C., Bis J.C., Blake T., Bochud M., Boehnke M., Boerwinkle E., Boomsma D.I., Bottinger E.P., Braund P.S., Brumat M., Campbell A., Campbell H., Chakravarti A., Chambers J.C., Chauhan G., Ciullo M., Cocca M., Collins F., Cordell H.J., Davies G., de Borst M.H., de Geus E.J., Deary I.J., Deelen J., Del Greco M.F., Demirkale C.Y., Dörr M., Ehret G.B., Elosua R., Enroth S., Erzurumluoglu A.M., Ferreira T., Frånberg M., Franco O.H., Gandin I., Gasparini P., Giedraitis V., Gieger C., Girotto G., Goel A., Gow A.J., Gudnason V., Guo X., Gyllensten U., Hamsten A., Harris T.B., Harris S.E., Hartman C.A., Havulinna A.S., Hicks A.A., Hofer E., Hofman A., Hottenga J.J., Huffman J.E., Hwang S.J., Ingelsson E., James A., Jansen R., Jarvelin M.R., Joehanes R., Johansson Å., Johnson A.D., Joshi P.K., Jousilahti P., Jukema J.W., Jula A., Kähönen M., Kathiresan S., Keavney B.D., Khaw K.T., Knekt P., Knight J., Kolcic I., Kooner J.S., Koskinen S., Kristiansson K., Kutalik Z., Laan M., Larson M., Launer L.J., Lehne B., Lehtimäki T., Liewald D.C., Lin L., Lind L., Lindgren C.M., Liu Y., Loos R.J., Lopez L.M., Lu Y., Lyytikäinen L.P., Mahajan A., Mamasoula C., Marrugat J., Marten J., Milaneschi Y., Morgan A., Morris A.P., Morrison A.C., Munson P.J., Nalls M.A., Nandakumar P., Nelson C.P., Niiranen T., Nolte I.M., Nutile T., Oldehinkel A.J., Oostra B.A., O'Reilly P.F., Org E., Padmanabhan S., Palmas W., Palotie A., Pattie A., Penninx B.W., Perola M., Peters A., Polasek O., Pramstaller P.P., Nguyen Q.T., Raitakari O.T., Ren M., Rettig R., Rice K., Ridker P.M., Ried J.S., Riese H., Ripatti S., Robino A., Rose L.M., Rotter J.I., Rudan I., Ruggiero D., Saba Y., Sala C.F., Salomaa V., Samani N.J., Sarin A.P., Schmidt R., Schmidt H., Shrine N., Siscovick D., Smith A.V., Snieder H., Sõber S., Sorice R., Starr J.M., Stott D.J., Strachan D.P., Strawbridge R.J., Sundström J., Swertz M.A., Taylor K.D., Teumer A., Tobin M.D., Tomaszewski M., Toniolo D., Traglia M., Trompet S., Tuomilehto J., Tzourio C., Uitterlinden A.G., Vaez A., van der Most P.J., van Duijn C.M., Vergnaud A.C., Verwoert G.C., Vitart V., Völker U., Vollenweider P., Vuckovic D., Watkins H., Wild S.H., Willemsen G., Wilson J.F., Wright A.F., Yao J., Zemunik T., Zhang W., Attia J.R., Butterworth A.S., Chasman D.I., Conen D., Cucca F., Danesh J., Hayward C., Howson J.M., Laakso M., Lakatta E.G., Langenberg C., Melander O., Mook-Kanamori D.O., Palmer C.N., Risch L., Scott R.A., Scott R.J., Sever P., Spector T.D., van der Harst P., Wareham N.J., Zeggini E., Levy D., Munroe P.B., Newton-Cheh C., Brown M.J., Metspalu A., Hung A.M., O’Donnell C.J., Edwards T.L., Psaty B.M., Tzoulaki I., Barnes M.R., Wain L.V., Elliott P, & Caulfield M.J. (2018). Genetic analysis of over one million people identifies 535 new loci associated with blood pressure traits. Nature genetics, 50(10), 1412-1425.
Publication 2018
African People Cardiovascular Diseases Cardiovascular System Cerebrovascular Accident Childbirth Europeans Genetic Diversity Genome-Wide Association Study High Blood Pressures Hospitalization Hypersensitivity Myocardial Infarction Population Group Single Nucleotide Polymorphism South Asian People Strains

Most recents protocols related to «Myocardial Infarction»

1
Bifidobacterium breve M-16V Probiotic Composition
Not available on PMC !

Example 4

Bifidobacterium breve M-16V (NITE BP-02622) is added to 3 mL of an MRS liquid medium and is anaerobically cultured at 37° C. for 16 hours, and the culture liquid is concentrated, followed by lyophilization, to obtain a lyophilized powder of the bacterium (bacterial powder). The bacterial powder and a prebiotic (lactulose, raffinose, and galactooligosaccharide) are uniformly mixed to obtain a composition. The composition is provided to elderly persons as a liquid food for the aged. The composition is daily provided at breakfast for one week such an amount that the intake of the Bifidobacterium breve M-16V (NITE BP-02622) is 1×1088 to 1×10110 CFU/kg body/day. When Bifidobacterium breve M-16V (NITE BP-02622) is killed cells, CFU/kg body/day can be replaced by (individual cells)/kg body/day. Note that the composition may be mixed with a food or drink, such as a fermented milk. By orally administering the composition, modulation of palatability, maintenance of body temperature, and protection of a blood vessel can be expected. Furthermore, the composition can be used for preventing or treating unbalanced diet, sensitivity to cold, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, or vascular plaque formation.

US11857579B2. Composition for promoting the secretion of FGF21 (2024-01-02). MORINAGA MILK INDUSTRY CO., LTD. [JP]. Inventors: Tatsuya Ehara [JP], Hirohisa Izumi [JP], Takashi Shimizu [JP].
Full text: Click here
Patent 2024
Arteriosclerosis Bacteria Bifidobacterium breve Blood Vessel Body Temperature Cardiac Hypertrophy Cells Cold Temperature Dental Plaque Diabetic Cardiomyopathies Diet fibroblast growth factor 21 Food Freeze Drying Human Body Hypersensitivity Lactulose Milk, Cow's Myocardial Infarction Powder Prebiotics Raffinose Reperfusion Injury secretion
2
Production of Bifidobacterium breve Powder
Not available on PMC !

Example 3

Bifidobacterium breve M-16V (NITE BP-02622) is added to 3 mL of an MRS liquid medium and is anaerobically cultured at 37° C. for 16 hours, and the culture liquid is concentrated, followed by lyophilization, to obtain a lyophilized powder of the bacterium (bacterial powder). Next, crystalline cellulose is put in an agitation granulator and mixed. Then, purified water was added, followed by granulation. The granulated product is dried to obtain granules that contain an extracted component of the bacterium and an excipient. By administering the composition, modulation of palatability, maintenance of body temperature, and protection of a blood vessel can be expected. Furthermore, the composition can be used for preventing or treating unbalanced diet, sensitivity to cold, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, or vascular plaque formation.

US11857579B2. Composition for promoting the secretion of FGF21 (2024-01-02). MORINAGA MILK INDUSTRY CO., LTD. [JP]. Inventors: Tatsuya Ehara [JP], Hirohisa Izumi [JP], Takashi Shimizu [JP].
Full text: Click here
Patent 2024
Arteriosclerosis Bacteria Bifidobacterium breve Blood Vessel Body Temperature Cardiac Hypertrophy Cellulose Cold Temperature Cytoplasmic Granules Diabetic Cardiomyopathies Diet Excipients fibroblast growth factor 21 Freeze Drying Hypersensitivity Myocardial Infarction Powder Reperfusion Injury secretion Senile Plaques
3
Predicting Atrial Fibrillation Risk
Not available on PMC !

Example 4

A cohort of patients with a recent history of myocardial infarction are administered an effective amount of the imaging agent of the invention, images of each patient's left atrium are obtained and the uptake of the imaging agent is quantified. The patients also undergo a resting flurpiridaz F 18 myocardial perfusion study and the summed rest score determined for each patient. Logisitic regression analysis is performed to produce an equation expressing the likelihood of future AF as a function of summed rest score and quantified imaging agent uptake.

US11865195B2. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging (2024-01-09). Lantheus Medical Imaging, Inc. [US], Yale University [US]. Inventors: Albert J. Sinusas [US], Joseph G. Akar [US], Richard R. Cesati [US], Heike S. Radeke [US], Stephen B. Haber [US].
Full text: Click here
Patent 2024
Atrial Fibrillation Atrium, Left Matrix Metalloproteinases Myocardial Infarction Myocardium Patients Perfusion
4
Probiotic-Milk Protein Composition for FGF21 Secretion
Not available on PMC !

Example 2

Bifidobacterium breve M-16V (NITE BP-02622) is added to 3 mL of an MRS liquid medium and is anaerobically cultured at 37° C. for 16 hours and the culture liquid is concentrated, followed by lyophilization, to obtain a lyophilized powder of the bacterium (bacterial powder). The bacterial powder and a dry powder of a milk protein concentrate (MPC480, manufactured by Fonterra, protein content: 80% by mass, casein: whey protein=about 8:2) are uniformly mixed to obtain a composition. 20 g of the composition is diluted in 200 g of water to obtain a composition for promoting the secretion of FGF21. By administering the composition, modulation of palatability, maintenance of body temperature, and protection of a blood vessel can be expected. Furthermore, the composition can be used for preventing or treating unbalanced diet, sensitivity to cold, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, or vascular plaque formation.

US11857579B2. Composition for promoting the secretion of FGF21 (2024-01-02). MORINAGA MILK INDUSTRY CO., LTD. [JP]. Inventors: Tatsuya Ehara [JP], Hirohisa Izumi [JP], Takashi Shimizu [JP].
Full text: Click here
Patent 2024
Arteriosclerosis Bacteria Bifidobacterium breve Blood Vessel Body Temperature Cardiac Hypertrophy Caseins Cold Temperature Diabetic Cardiomyopathies Diet fibroblast growth factor 21 Freeze Drying Hypersensitivity Milk, Cow's Myocardial Infarction Powder Proteins Reperfusion Injury secretion Senile Plaques Staphylococcal Protein A Whey Proteins
5
Sociodemographic Factors and USOC/HL Associations
Covariate selection was guided by previous literature on sociodemographic and health characteristics associated with having a USOC or HL (10 (link),11 (link)). These include baseline, age, race/ethnicity (White, Black, Hispanic, and other), sex, marital status (married/living with partner, and single/never married/divorced/widow), education (less than high school, high school diploma or equivalent, and some college or more), household income (under the poverty line, 100%–199% the poverty line, and ≥200% of the poverty line), number of chronic health conditions among heart attack, heart disease, high blood pressure, arthritis, osteoporosis, diabetes, lung disease, stroke, or cancer (0, 1–2, 3–5, or 6+), self-reported health status (Likert scale, 1 = Excellent, …, 5 = Poor), number of activities of daily living (ADLs) for which the respondent reported needing help (none, 1–2 ADLs, and 3≤ ADLs), dementia (probable, possible, and no dementia) (20 ), additional health coverage (Medigap/Medicare supplement, Medicaid, or Tricare), and depression status (based on Patient Health Questionnaire-2 scores ≥3) (21 (link)).
Despite being identified as a risk factor for loss of USOC, experiencing transportation barriers (reporting that a transportation problem restricted any activity participation in the month before the interview) was not included in the main analyses due to data availability, as a total of N = 1 804 participants had missing information.
Garcia Morales E., Assi L., Powell D., Luu K, & Reed N. (2023). The Association Between Self-Reported Hearing Loss and Loss of Usual Source of Health Care Among Older Medicare Beneficiaries: Evidence From the National Health and Aging Trends Study. Innovation in Aging, 7(2), igad002.
Full text: Click here
Publication 2023
Arthritis Cerebrovascular Accident Dementia Diabetes Mellitus Dietary Supplements Ethnicity Heart Diseases High Blood Pressures Hispanics Households Insurance, Medigap Lung Diseases Malignant Neoplasms Myocardial Infarction Osteoporosis Training Programs Widow

Top products related to «Myocardial Infarction»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Triphenyl tetrazolium chloride (ttc) by Merck Group
Sourced in United States, Germany, Sao Tome and Principe, Macao, China, Switzerland, Australia, Japan, Spain, Italy, Senegal
The TTC (Triphenyltetrazolium Chloride) is a laboratory reagent used for various analytical and diagnostic applications. It is a colorless compound that is reduced to a red formazan product in the presence of metabolically active cells or tissues. This color change is utilized to assess cell viability, detect active enzymes, and measure cellular respiration in a wide range of biological samples.
3
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
4
Image pro plus 6 by Media Cybernetics
Sourced in United States, Japan, Germany, United Kingdom, China, Hungary, Singapore, Canada, Switzerland
Image-Pro Plus 6.0 is a comprehensive image analysis software package designed for scientific and industrial applications. It provides a wide range of tools for image capture, enhancement, measurement, analysis, and reporting.
5
Evans blue by Merck Group
Sourced in United States, Germany, Sao Tome and Principe, China, United Kingdom, Macao, Spain, Japan, Ireland, Italy
Evans blue is a dye used as a laboratory reagent. It is a blue-colored dye that binds to albumin in the blood, allowing for the measurement and visualization of blood volume and albumin distribution. The dye has a strong blue color and is soluble in water.
6
Image pro plus software by Media Cybernetics
Sourced in United States, Japan, Germany, United Kingdom, Canada, China, Denmark
Image-Pro Plus is an image analysis software developed by Media Cybernetics. It provides tools for image acquisition, processing, measurement, and analysis.
7
Sas software by SAS Institute
Sourced in United States, Japan, Austria, Germany, United Kingdom, France, Cameroon, Denmark, Israel, Sweden, Belgium, Italy, China, New Zealand, India, Brazil, Canada
SAS software is a comprehensive analytical platform designed for data management, statistical analysis, and business intelligence. It provides a suite of tools and applications for collecting, processing, analyzing, and visualizing data from various sources. SAS software is widely used across industries for its robust data handling capabilities, advanced statistical modeling, and reporting functionalities.
8
Vevo 2100 by Fujifilm
Sourced in Canada, United States, Japan
The Vevo 2100 is a high-resolution, real-time in vivo imaging system designed for preclinical research. It utilizes advanced ultrasound technology to capture detailed images and data of small animal subjects.
9
Evans blue dye by Merck Group
Sourced in United States, Germany, Sao Tome and Principe, United Kingdom, Japan, Macao, Brazil
Evans blue dye is a lab equipment product used as a dye for various research applications. It is a blue azo dye with the chemical formula C₃₄H₂₄N₆Na₄O₁₄S₄. The core function of Evans blue dye is to act as a marker or tracer in biological studies and experiments.
10
Ttc solution by Merck Group
Sourced in United States, Switzerland, Germany
The TTC solution is a laboratory reagent used for various applications in cell biology and microbiology. It is a colorimetric dye that is used to assess the viability and metabolic activity of cells. The solution is primarily composed of the compound 2,3,5-triphenyltetrazolium chloride (TTC), which is reduced by active cellular enzymes to produce a red formazan dye. The intensity of the color change is proportional to the level of cellular activity, making the TTC solution a useful tool for quantifying cell viability and proliferation.

More about "Myocardial Infarction"

Myocardial infarction, also known as heart attack, is a serious medical condition where the blood supply to a part of the heart muscle is suddenly blocked, often due to a blood clot.
This can lead to damage or death of the affected heart tissue.
Symptoms of myocardial infarction may include chest pain, shortness of breath, and nausea.
Timely treatment is crucial to minimize damage and improve outcomes.
To optimize myocardial infarction research, tools like PubCompare.ai can be utilized.
This AI platform helps researchers locate the best protocols from literature, preprints, and patents, and leverages AI-driven comparisons to enhance reproducibility and accuracy, ensuring the research is on the right track.
Researchers may also consider using other analytical tools and techniques, such as SAS version 9.4, TTC (triphenyltetrazolium chloride) staining, Image-Pro Plus 6.0 software, Evans blue dye, and the Vevo 2100 imaging system, to further investigate and understand the pathophysiology of myocardial infarction.
These tools and techniques can provide valuable insights into the extent of tissue damage, the effectiveness of interventions, and the overall progression of the condition.
By incorporating a comprehensive understanding of myocardial infarction and leveraging the latest technologies and software, researchers can optimize their research efforts, improve the quality of their findings, and contribute to the advancement of our knowledge and treatment of this serious cardiovascular condition.